Inhibikase Therapeutics, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 0.70M3.10M0.12M0.26M
Operating items
Research & Development 0.89M11.36M12.03M13.62M17.21M
Selling, General & Administrative 2.62M6.51M6.22M6.73M11.38M
Operating Expenses 3.52M17.87M18.25M20.35M28.59M
Operating Income -2.82M-14.77M-18.13M-20.09M-28.59M
EBIT -2.82M-14.77M-18.13M-20.09M-28.59M
Net income details
EBT -2.85M-14.79M-18.13M-20.09M-28.59M
Profit After Tax -2.85M-14.79M-18.05M-19.03M-27.52M
Income from Continuing Operations -2.85M-14.79M-18.13M-20.09M-28.59M
Consolidated Net Income -2.85M-14.79M-18.13M-20.09M-28.59M
Income towards Parent Company -2.85M-14.79M-18.13M-20.09M-28.59M
Net Income towards Common Stockholders -2.85M-14.79M-18.13M-20.09M-28.59M
Additional items
EPS (Basic) -0.35-0.81-4.28-3.16-1.16
EPS (Weighted Average and Diluted) -0.81-4.28-3.16-1.16
Shares Outstanding (Weighted Average) 1.60M4.19M4.20M6.17M67.19M
Shares Outstanding (Diluted Average) 18.21M4.22M6.03M23.71M
EBITDA -2.82M-14.77M-18.13M-20.09M-28.59M
Interest Expenses 0.03M0.02M